Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00571662 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy of Pentostatin and Low Dose TBI With Allogenic Peripheral Blood Stem Cell Transplant
A Phase 2 study, sponsored by University of Nebraska.
- Completed
- Registry status
- Phase 2
- Development phase
- 76
- Enrollment target
NCT00571662 is a Phase 2 study that has completed, run by University of Nebraska. The registered enrollment target is 76 participants.
The verdict
NCT00571662, a Phase 2 study, has completed, sponsored by University of Nebraska.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 76 participants
- Enrollment target
Study Summary
This is a continuation of a pilot study which is now regarded as a phase II trial with a plan to enroll an additional 40 patients (20 related and 20 unrelated donor transplants) with hematological malignancy assessing the safety and efficacy of a minimally myelosuppressive regimen with pentostatin and low-dose total body irradiation (TBI) followed by allogeneic peripheral blood stem cell transplantation (alloPSCT).
Interventions
- DRUG G-CSF
- DRUG Mycophenolate Mofetil (MMF)
- DRUG Pentostatin
- RADIATION Total-body irradiation (TBI)
- DRUG Cyclosporine A (CsA)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 76 participants |
| Start Date | 2000-12-08 |
| Est. Completion | 2008-12-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00571662
The ClinicalTrials.gov registry entry for NCT00571662 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 76 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Nebraska, which has 407 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which G-CSF is the first listed.
NCT00571662 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00571662 about?
NCT00571662 is a clinical study titled "Safety and Efficacy of Pentostatin and Low Dose TBI With Allogenic Peripheral Blood Stem Cell Transplant". This is a continuation of a pilot study which is now regarded as a phase II trial with a plan to enroll an additional 40 patients (20 related and 20 unrelated donor transplants) with hematological malignancy assessing the safety and efficacy of a minimally myelosuppressive regimen with pentostatin a...
What is the current status of trial NCT00571662?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 76 participants. The study started on 2000-12-08. Estimated completion is 2008-12-30.
What interventions are being tested in trial NCT00571662?
The interventions under investigation include: G-CSF (DRUG), Mycophenolate Mofetil (MMF) (DRUG), Pentostatin (DRUG), Total-body irradiation (TBI) (RADIATION), Cyclosporine A (CsA) (DRUG).
Who is sponsoring clinical trial NCT00571662?
This trial is sponsored by University of Nebraska, which has 407 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.